The Centers for Disease Control and Prevention awarded multiple indefinite delivery contracts under a competitive solicitation to purchase standard adult vaccines. The contracts have a one year period of performance from July 1, 2022 to June 30, 2023 and a combined potential value of $85.6 million. Merck Sharp & Dohme LLC was awarded one of these contracts as the prime contractor. The contracts enable the CDC to order 12 types of adult vaccines for delivery within 15 business days....
The Centers for Disease Control and Prevention awarded multiple indefinite delivery contracts to Merck Sharp & Dohme LLC for adult vaccines. The contracts have a potential value of $83,485,760 and a period of performance from July 1, 2021 to June 30, 2022. Merck will provide 13 standard adult vaccines including hepatitis A, hepatitis B, pneumococcal polysaccharide, tetanus/diphtheria toxoids, herpes zoster, measles/mumps/rubella, meningococcal conjugate, human papillomavirus, and...
The Centers for Disease Control and Prevention (CDC) has awarded Pfizer Inc. an Indefinite Delivery Contract (IDC) for the supply of various adult vaccines to support immunization programs under Section 317(j) of the Public Health Service Act. The $103,060,230.33 contract, which runs from July 1, 2023 to June 30, 2024, covers a range of vaccines including hepatitis A, hepatitis B, pneumococcal polysaccharide, tetanus and diphtheria toxoids, herpes zoster, measles-mumps-rubella, meningococcal...
The Centers for Disease Control and Prevention (CDC) has awarded an Indefinite Delivery, Indefinite Quantity (IDIQ) contract to Dynavax Technologies Corporation, valued at up to $56,203,651.08, to supply various adult vaccines over a one-year period from July 1, 2023 through June 30, 2024. The vaccines to be delivered include hepatitis A, hepatitis B, hepatitis A & B combination, pneumococcal polysaccharide, tetanus and diphtheria toxoids, herpes zoster, tetanus, reduced diphtheria toxoid...
The Centers for Disease Control and Prevention (CDC), National Center for Immunization and Respiratory Diseases (NCIRD) awarded an indefinite-delivery, indefinite-quantity (IDIQ) contract to Merck Sharp & Dohme LLC, doing business as Merck, for the supply of various adult vaccines. The contract has a potential value of $87,753,075 and a period of performance from July 1, 2023 through June 30, 2024. The vaccines will be delivered within 15 business days of order receipt and shipped FOB...
The Centers for Disease Control and Prevention awarded multiple indefinite delivery contracts to Sanofi Pasteur Inc. for the procurement of adult vaccines. The contracts have a potential value of $39.08 million to supply 13 standard adult vaccines over a one year period from July 1, 2021 through June 30, 2022. Vaccines will be delivered within 15 business days of order to support immunization programs in 50 state health departments and large cities, as provided under Section 317(j) of the Public...
The Centers for Disease Control and Prevention (CDC), National Center for Immunization and Respiratory Diseases (NCIRD) awarded an indefinite delivery, indefinite quantity (IDIQ) contract valued up to $25.35 million to VBI Vaccines (Delaware) Inc., doing business as VBI Vaccines Inc., a foreign-owned for-profit corporation. The contract covers the supply of 12 different adult vaccines from July 2024 through June 2025, including vaccines for hepatitis A/B, pneumococcal disease,...
The Centers for Disease Control and Prevention (CDC), National Center for Immunization and Respiratory Diseases (NCIRD) awarded an Indefinite Delivery/Indefinite Quantity (ID/IQ) contract to Bavarian Nordic, Inc. for the procurement of various adult vaccines. The $99,015,000 multiple-award contract has a period of performance from July 1, 2024 to June 30, 2025. The contract does not utilize any set-asides. The solicitation seeks the purchase of vaccines for Hepatitis A, Hepatitis B, Hepatitis...
The Centers for Disease Control and Prevention (CDC), National Center for Immunization and Respiratory Diseases (NCIRD) has awarded a 5-year, $154.3 million indefinite delivery, indefinite quantity (IDIQ) contract to Glaxosmithkline, LLC for the provision of various adult vaccines. The contract period of performance is from July 1, 2024 to June 30, 2025, with vaccines ordered via the CDC's Vaccine Tracking System (VTrckS) using a fair opportunity process. The required vaccine types include...
This Indefinite Delivery Contract (IDC) award from the Centers for Disease Control and Prevention (CDC) is for the procurement of 12 standard adult vaccines to support state health department immunization programs. The $62,183,800 multiple-award contract has a period of performance from July 1, 2022 to June 30, 2023. The prime contractor is Pfizer Inc., a large pharmaceutical manufacturer that serves as a major federal supplier of medical products and vaccines. The contract requires the delivery...